SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics
12 juil. 2023 07h00 HE
|
SparingVision
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics SparingVision remains focused on in vivo genomic medicines, with SPVN20, a GIRK-based gene therapy candidate, expected to reach...